Abstracts tagged "Damage Index"

Abstract Number: 2374 • ACR Convergence 2024
Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia
Omer Uludag¹, Sarvan Aghamuradov¹, Cansu Erel Gezegen², Marjan Jabbarli², Ismat Habibov², Ahmet Oguz Celik², Yasemin Yalcinkaya¹, Ahmet Gul¹, Murat Inanc¹ and Bahar Artim Esen¹, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey
Background/Purpose: Thrombocytopenia has been reported at frequencies ranging from 10 to 40 % in different cohorts. Treatment can be challenging and due to its considerable…
Abstract Number: 0118 • ACR Convergence 2024
Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Erik Cimé-Aké¹, Gabriela Hernández-Molina², Amaya Llorente-Chávez³ and Eduardo Martin Nares², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Hematology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: The 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) were recently published. The new criteria require an entry criterion and employe a…
Abstract Number: 2375 • ACR Convergence 2024
Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?
Burak Kundakci¹, Megan Barber², Ann E. Clarke², Sindhu Johnson³, Ian Bruce¹ and On behalf of the revised SLE organ damage index (SDI) collaborators⁴, ¹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: The Systemic Lupus International Collaborating Clinics (SLICC), Lupus Foundation of America (LFA), and American College of Rheumatology (ACR) are leading a global initiative to…
Abstract Number: 0122 • ACR Convergence 2024
Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome
Evelyn Aranda Cano¹, Jessica Roldan Ortega², Yaneli Juárez-Vicuña³, Fausto Sánchez Muñoz⁴, Itzel Palafox Sosa⁵, Luz Angelica Viruel-Mejia⁶, David Vera Bustamante⁷, Luis H. Silveira Torre⁸, Angélica Vargas Guerrero⁹, Mayra Nadia Quintanar-Cuevas¹⁰, Erick Giovanny Bautista Jímenez¹¹ and Laura Aline Martinez-Martinez¹², ¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Mexico, ²Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³Instituto Nacional del Cardiología Ignacio Chávez, México, Distrito Federal, Mexico, ⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁵Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, ⁶Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, ⁷Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, ⁸Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁹Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ¹⁰Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, México, Mexico, ¹¹Hospital General de Zona No. 27 del Instituto Mexicano del Seguro Social, Mexico, Distrito Federal, Mexico, ¹²Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico
Background/Purpose: Growth differentiation factor 15 (GDF-15), is a stress induced inflammatory cytokine, member of the transforming growth factor-β superfamily, tissue injury. It is predominantly expressed…
Abstract Number: 2403 • ACR Convergence 2024
Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study
Fernando A Oliveira¹, Fabiana Moura², Ana Flávia Dias³, Claudia Santoro³, Fernando Pereira², Rosa Telles² and Cristina Lanna², ¹Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ²Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ³Grupo Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: Body image of systemic lupus erythematosus (SLE) patients is affected by the mucocutaneous manifestations and its scars, in particular related to discoid lupus. The…
Abstract Number: 0493 • ACR Convergence 2023
Axial Disease Activity in Psoriatic Arthritis Is Higher in Patients with Carotid Plaque
Rosa Arvizu-Rivera¹, Valeria Gonzalez-Gonzalez², Dionicio A. Galarza-Delgado³, Iris Colunga³, José Ramón Azpiri-López³, Victor Beltran⁴, Angel Arias Peralta⁵ and Jesus Alberto Cardenas-De la Garza⁶, ¹Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario UANL, Monterrey, Mexico, ⁴Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Approximately half of the patients with psoriatic arthritis (PsA) present with axial disease. Previously, it was reported that PsA-patients with axial involvement present a…
Abstract Number: 0606 • ACR Convergence 2023
Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when…
Abstract Number: 1170 • ACR Convergence 2023
Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…
Abstract Number: 1451 • ACR Convergence 2023
Evaluation of Changes in SLE Patients’ Phenotype at Disease Onset, and Assessment of Disease Activity, Damage and Therapy at Diagnosis and During Follow up in the Last Forty Years: Preliminary Data of a Single Center Experience
Micaela Fredi¹, Silvia Ebe Lucia Della Pina¹, Claudia Barison¹, Chiara Orlandi¹, Marzia Tedeschi², Mai Chiara², Cecilia Nalli¹ and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²University of Brescia, Brescia, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with a high degree of variability at onset, which may make SLE diagnosis challenging, with…
Abstract Number: 1452 • ACR Convergence 2023
Inflammatory Markers and Left Ventricular Dysfunction in Systemic Lupus Erythematosus (SLE)
Audrey Hagiwara, Moumita Bose, Marianne Bernardo, Michael Nelson, Mariko Ishimori, Daniel Berman, C. Noel Bairey Merz, janet wei and Caroline Jefferies, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Women with SLE have an elevated risk of cardiovascular disease. Many women with SLE frequently report chest pain in the absence of obstructive coronary…
Abstract Number: 1459 • ACR Convergence 2023
Unveiling the Impact of Neuropsychiatric Involvement in Systemic Lupus Erythematosus on Damage Accrual
Dionysis Nikolopoulos¹, Nursen Cetrez², Julius Lindblom² and Ioannis Parodis², ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The link between neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) and heightened morbidity, mortality, and organ damage, as well as detrimental impacts on health-related…
Abstract Number: 1462 • ACR Convergence 2023
Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)
Sara garcia Perez¹, Jose-Maria Pego-Reigosa², Irene Altabás González¹, Norman Jiménez³, Victor Del campo Perez⁴, JULIA MARTINEZ BARRIO⁵, Maria Galindo-Izquierdo⁶, Jaime Calvo- Alén⁷, Esther Uriarte Isacelaya⁸, Eva Tomero Muriel⁹, Mercedes Freire González¹⁰, Victor Martinez-Taboada¹¹, Paloma Vela¹², Antonio Fernandez-Nebro¹³, Alejandro Olivé-Marqués¹⁴, Javier Narvaez¹⁵, Raúl Menor-Almagro¹⁶, Gregorio Santos Soler¹⁷, José Ángel Hernández Beriain¹⁸, Javier Manero ruiz¹⁹, Elena Aurrecoechea Aguinaga²⁰, Oihane Ibarguengoitia-Barrena²¹, Carlos Montilla-Morales²², Gema Bonilla²³, Vicente Torrente-Segarra²⁴, Ana Paula Cacheda²⁵, Maria J. García-Villanueva²⁶, Clara Moriano Morales²⁷, Concepción Fito Manteca²⁸, Cristina Bohórquez²⁹, Nuria Lozano Rivas³⁰ and Iñigo Rúa-Figueroa³¹, ¹Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁴Department of Epidemiology, University Hospital of Vigo, IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ⁵Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁶Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ⁹Rheumatology, Hospital La Princesa, Madrid, Spain, ¹⁰Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹¹Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹²Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, ¹³Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁴Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ¹⁷Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ¹⁸Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ¹⁹Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, ²⁰Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²¹Galdakao-Usansolo University Hospital, Bilbao, Spain, ²²Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²³Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁴Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ²⁵Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, ²⁶Hospital Ramón y Cajal, Madrid, Spain, ²⁷Rheumatology, Hospital Universitario de León, León, Spain, ²⁸Department of Rheumatology, University Hospital of Navarra, Pamplona, Spain, ²⁹Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, ³⁰Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ³¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) survival has improved during recent decades, so other outcomes like damage accrual become more relevant. Damage represents that clinical feature…
Abstract Number: 1567 • ACR Convergence 2023
Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis
Tanaz Kermani¹, SEMA KAYMAZ-TAHRA², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Antoine G Sreih¹², Kenneth Warrington¹³, fatma Alibaz-Öner¹⁴, Haner Direskeneli¹⁵ and Peter Merkel⁷, ¹Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ²Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Bristol Myers Squibb, Princeton Pike, NJ, ¹³Mayo Clinic, Rochester, MN, ¹⁴Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ¹⁵Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
Background/Purpose: Damage is the irreversible consequence of disease or its treatment. This study aimed to evaluate the accrual of damage in Takayasu's arteritis (TAK) using…
Abstract Number: 2265 • ACR Convergence 2023
Lupus Damage Index Revision – Item Generation and Reduction Phase
Burak Kundakci¹, Megan Barber², Ann Clarke², Sindhu Johnson³, Ian Bruce⁴ and On behalf of the revised SLE organ damage index (SDI) collaborators⁴, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, ²University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: The SDI is a robust instrument, but is limited by incomplete items, restricted applicability in paediatric patients, and outdated item definitions1. The SLICC, ACR…
Abstract Number: 2280 • ACR Convergence 2023
The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort
Manuel Ugarte-Gil¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz², Cristina Reategui-Sokolova³, Claudia Elera-Fitzcarrald⁴, Erika Noriega⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela S Alarcón⁷, ¹Universidad Cientifica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad San Ignacio de Loyola, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Privada San Juan Bautista, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ⁶Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁷Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) clinican-reported outcome (ClinRO) correlates well with other disease activity indices such us…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].